Abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory disease. The latest research on the pathogenesis of HS has provided new ideas for therapies. A number of studies have shown that targeted biological agents targeting specific cytokines involved in HS are effective. The update of monoclonal antibodies against IL-17, TNF, IL-1, IL-12/IL-23, JAK/STAT pathway inhibitors, complement C5a inhibitors and phosphodiesterase inhibitors in the treatment of HS is reviewed in this paper.

Key words: hidradenitis suppurativa, biological agents, monoclonal antibodies